143 related articles for article (PubMed ID: 34646075)
1. Differential expression of estrogen receptor subtypes in ovarian high-grade serous carcinoma and clear cell carcinoma.
Osaku D; Oishi T; Kawamura N; Iida Y; Komatsu H; Kudoh A; Chikumi J; Sato S; Harada T
Reprod Med Biol; 2021 Oct; 20(4):467-476. PubMed ID: 34646075
[TBL] [Abstract][Full Text] [Related]
2. Role of GPER on proliferation, migration and invasion in ligand-independent manner in human ovarian cancer cell line SKOV3.
Yan Y; Jiang X; Zhao Y; Wen H; Liu G
Cell Biochem Funct; 2015 Dec; 33(8):552-9. PubMed ID: 26526233
[TBL] [Abstract][Full Text] [Related]
3. G Protein-Coupled Estrogen Receptor Correlates With Dkk2 Expression and Has Prognostic Impact in Ovarian Cancer Patients.
Fraungruber P; Kaltofen T; Heublein S; Kuhn C; Mayr D; Burges A; Mahner S; Rathert P; Jeschke U; Trillsch F
Front Endocrinol (Lausanne); 2021; 12():564002. PubMed ID: 33679613
[TBL] [Abstract][Full Text] [Related]
4.
Park SJ; Lim W; Mun J; Paik H; Park S; Lim H; Kim J; Lee EJ; Yim GW; Lee N; Lee C; Kim JW; Song G; Kim HS
In Vivo; 2021; 35(5):2647-2653. PubMed ID: 34410952
[TBL] [Abstract][Full Text] [Related]
5. Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy.
Li M; Li H; Liu F; Bi R; Tu X; Chen L; Ye S; Cheng X
J Ovarian Res; 2017 Feb; 10(1):9. PubMed ID: 28187748
[TBL] [Abstract][Full Text] [Related]
6. Differential expression of estrogen receptor subtypes and variants in ovarian cancer: effects on cell invasion, proliferation and prognosis.
Chan KKL; Siu MKY; Jiang YX; Wang JJ; Wang Y; Leung THY; Liu SS; Cheung ANY; Ngan HYS
BMC Cancer; 2017 Aug; 17(1):606. PubMed ID: 28859612
[TBL] [Abstract][Full Text] [Related]
7. Anterior gradient protein 2 (AGR2) is an independent prognostic factor in ovarian high-grade serous carcinoma.
Darb-Esfahani S; Fritzsche F; Kristiansen G; Weichert W; Sehouli J; Braicu I; Dietel M; Denkert C
Virchows Arch; 2012 Aug; 461(2):109-16. PubMed ID: 22752467
[TBL] [Abstract][Full Text] [Related]
8. Profile of differentially expressed miRNAs in high-grade serous carcinoma and clear cell ovarian carcinoma, and the expression of miR-510 in ovarian carcinoma.
Zhang X; Guo G; Wang G; Zhao J; Wang B; Yu X; Ding Y
Mol Med Rep; 2015 Dec; 12(6):8021-31. PubMed ID: 26497752
[TBL] [Abstract][Full Text] [Related]
9. Global miRNA expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed miRNAs including miR-200c-3p as a prognostic marker.
Vilming Elgaaen B; Olstad OK; Haug KB; Brusletto B; Sandvik L; Staff AC; Gautvik KM; Davidson B
BMC Cancer; 2014 Feb; 14():80. PubMed ID: 24512620
[TBL] [Abstract][Full Text] [Related]
10. G Protein-Coupled Estrogen Receptor Mediates Cell Proliferation through the cAMP/PKA/CREB Pathway in Murine Bone Marrow Mesenchymal Stem Cells.
Chuang SC; Chen CH; Chou YS; Ho ML; Chang JK
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899453
[TBL] [Abstract][Full Text] [Related]
11. G protein-coupled estrogen receptor 1 (GPER-1) and agonist G-1 inhibit growth of ovarian cancer cells by activation of anti-tumoral transcriptome responses: impact of GPER-1 mRNA on survival.
Schüler-Toprak S; Skrzypczak M; Ignatov T; Ignatov A; Ortmann O; Treeck O
J Cancer Res Clin Oncol; 2020 Dec; 146(12):3175-3188. PubMed ID: 32813115
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of HER3 based on protein and mRNA expression in high-grade serous ovarian carcinoma.
Unger U; Denkert C; Braicu I; Sehouli J; Dietel M; Loibl S; Darb-Esfahani S
Virchows Arch; 2017 Feb; 470(2):143-151. PubMed ID: 27913862
[TBL] [Abstract][Full Text] [Related]
13. The Co-Expression of Estrogen Receptors ERα, ERβ, and GPER in Endometrial Cancer.
Hojnik M; Sinreih M; Anko M; Hevir-Kene N; Knific T; Pirš B; Grazio SF; Rižner TL
Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769338
[TBL] [Abstract][Full Text] [Related]
14. A novel estrogen receptor GPER mediates proliferation induced by 17β-estradiol and selective GPER agonist G-1 in estrogen receptor α (ERα)-negative ovarian cancer cells.
Liu H; Yan Y; Wen H; Jiang X; Cao X; Zhang G; Liu G
Cell Biol Int; 2014 May; 38(5):631-8. PubMed ID: 24446390
[TBL] [Abstract][Full Text] [Related]
15. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
16. Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study.
Köbel M; Madore J; Ramus SJ; Clarke BA; Pharoah PD; Deen S; Bowtell DD; Odunsi K; Menon U; Morrison C; Lele S; Bshara W; Sucheston L; Beckmann MW; Hein A; Thiel FC; Hartmann A; Wachter DL; Anglesio MS; Høgdall E; Jensen A; Høgdall C; Kalli KR; Fridley BL; Keeney GL; Fogarty ZC; Vierkant RA; Liu S; Cho S; Nelson G; Ghatage P; Gentry-Maharaj A; Gayther SA; Benjamin E; Widschwendter M; Intermaggio MP; Rosen B; Bernardini MQ; Mackay H; Oza A; Shaw P; Jimenez-Linan M; Driver KE; Alsop J; Mack M; Koziak JM; Steed H; Ewanowich C; DeFazio A; Chenevix-Trench G; Fereday S; Gao B; Johnatty SE; George J; Galletta L; ; Goode EL; Kjær SK; Huntsman DG; Fasching PA; Moysich KB; Brenton JD; Kelemen LE
Br J Cancer; 2014 Dec; 111(12):2297-307. PubMed ID: 25349970
[TBL] [Abstract][Full Text] [Related]
17. SLFN11 is a BRCA Independent Biomarker for the Response to Platinum-Based Chemotherapy in High-Grade Serous Ovarian Cancer and Clear Cell Ovarian Carcinoma.
Akashi H; Yachida N; Ueda H; Yamaguchi M; Yamawaki K; Tamura R; Suda K; Ishiguro T; Adachi S; Nagase Y; Ueda Y; Ueda M; Abiko K; Kagabu M; Baba T; Nakaoka H; Enomoto T; Murai J; Yoshihara K
Mol Cancer Ther; 2024 Jan; 23(1):106-116. PubMed ID: 37717249
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 Expression and CD8+ Tumor-infiltrating Lymphocytes in Different Types of Tubo-ovarian Carcinoma and Their Prognostic Value in High-grade Serous Carcinoma.
Chen H; Molberg K; Strickland AL; Castrillon DH; Carrick K; Jiang Q; Niu S; Rivera-Colon G; Gwin K; Hinson S; Lea J; Miller DS; Zheng W; Lucas E
Am J Surg Pathol; 2020 Aug; 44(8):1050-1060. PubMed ID: 32384321
[TBL] [Abstract][Full Text] [Related]
19. Increased expression of neurotensin in high grade serous ovarian carcinoma with evidence of serous tubal intraepithelial carcinoma.
Norris EJ; Zhang Q; Jones WD; DeStephanis D; Sutker AP; Livasy CA; Ganapathi RN; Tait DL; Ganapathi MK
J Pathol; 2019 Jul; 248(3):352-362. PubMed ID: 30883751
[TBL] [Abstract][Full Text] [Related]
20. Comparison of clinical behavior between mucinous ovarian carcinoma with infiltrative and expansile invasion and high-grade serous ovarian carcinoma: a retrospective analysis.
Hada T; Miyamoto M; Ishibashi H; Matsuura H; Kakimoto S; Iwahashi H; Tsuda H; Takano M
Diagn Pathol; 2022 Jan; 17(1):12. PubMed ID: 35057833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
